Podcasts about arndt vogel

In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to switch. The discussion covers a range of topics, including 2nd line options for advanced HCC after progression on 1st line TKIs and IO-based therapies, as well as: How to approach sequencing in clinical practice The available data supporting sequencing strategies When to switch to 2nd line therapy and what to consider when doing so This is the second video podcast episode in a 4-part series. Access the rest of the series here: Part 1 - The use of IO in unresectable HCC Part 3 - Intermediate HCC: treatment options and strategies (coming soon) Part 4 - The evolving role of IO in intermediate HCC (coming soon)   Clinical takeaways Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life. Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation.   Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!   Website: http://www.oncbrothers.com/   X/Twitter: https://twitter.com/oncbrothers   Contact us at info@oncbrothers.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Krebserkrankungen der Gallenwege, insbesondere Cholangiokarzinome (CCA), gewinnen weltweit an Bedeutung. Mit einer Prävalenz von 10-20% ist das CCA der zweithäufigste primäre Lebertumor. Die steigende Inzidenz des CCA wird durch globale Entwicklungen, einschließlich Fettlebererkrankungen, beeinflusst. In den letzten Jahren hat die frühzeitige Erkennung spezifischer genetischer Aberrationen an Bedeutung gewonnen und entscheidend dazu beigetragen, personalisierte Therapieansätze zu finden. In der ersten Folge der neuen Staffel von O-Ton Onkologie erklärt Prof. Dr. med. Arndt Vogel, Longo Family Chair in Liver Cancer Research, University of Toronto, im Gespräch mit Dr. med. vet. Astrid Heinl, stellv. Chefredakteurin des Journal Onkologie, welche Fortschritte in den systemischen Therapien, Immun- und zielgerichteten Therapien Hoffnung auf verbesserte Überlebenszeiten geben könnten. Zur Folgen-Übersicht: medical-tribune.de/o-ton-onkologie - Webseite von Prof. Dr. med. Arndt Vogel, MD/PhD des University Health Networks, Toronto

In dieser Folge widmen wir uns der zunehmenden Bedeutung molekularer Tumoranalysen als Grundlage der Präzisionsmedizin bei gastroenterologischen Tumoren. Hierzu sprechen wir mit Prof. Dr. med. Arndt Vogel. Er ist leitender Oberarzt der Klinik für Gastroenterologie, Hepatologie, Endokrinologie der Medizinischen Hochschule Hannover.

Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise

Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise

Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise

Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise

Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise

Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC

Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC

Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC

Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC

Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC

Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC

Professor Arndt Vogel from Hannover Medical School in Germany discusses major clinical trials and recent changes in the treatment of advanced hepatocellular carcinoma. CME information and select publications [here] (http://www.researchtopractice.com/OncologyTodayHCC22)

Featuring a discussion on recent advances in the clinical management of advanced HCC with Professor Arndt Vogel, moderated by Dr Neil Love.

Featuring a discussion on recent advances in the clinical management of advanced HCC with Professor Arndt Vogel, moderated by Dr Neil Love.

Featuring a discussion on recent advances in the clinical management of advanced HCC with Professor Arndt Vogel, moderated by Dr Neil Love.

Please visit answersincme.com/YBC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology discusses the evidence for combining immune checkpoint inhibitors (ICIs) with chemotherapy in the treatment of advanced biliary tract cancer and provides a clinical perspective on the future role of these combinations in the treatment landscape. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for investigating ICI plus chemotherapy combinations in the treatment of advanced biliary tract cancer; Discuss the efficacy and safety of late-stage emerging ICI plus chemotherapy combinations being investigated for the first-line treatment of advanced biliary tract cancer, compared to conventional therapy options; and Summarize clinical considerations for the future use of emerging ICI plus chemotherapy combinations in the first-line treatment of advanced biliary tract cancer.

In this episode, Jonathan Sackier is joined by Arndt Vogel, committee member of the European Society for Medical Oncology (ESMO). The pair discuss Vogel's career, his role within the organisation, the recent ESMO Congress, and key themes of cancer care.